Journey Colab

Journey Colab was a U.S.-based private biopharmaceutical company focused on developing psychedelic therapies for addiction and related mental health disorders. Its lead program was synthetic mescaline hydrochloride, developed for alcohol use disorder, with the broader strategy of pairing neuroplasticity-promoting compounds with psychotherapy and community-based care. The company positioned itself at the intersection of biotech and care delivery, seeking FDA approval for regulated psychedelic therapeutics while also designing a treatment model around those medicines. Public sources indicate the company was founded in 2020 in San Francisco and raised venture financing from a group of healthcare, technology, and impact-oriented investors. More recent private-market data indicates the company became out of business in January 2025.